Published in J Natl Cancer Inst Monogr on January 01, 2006
Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med (2009) 4.60
Improvements in US Breast Cancer Survival and Proportion Explained by Tumor Size and Estrogen-Receptor Status. J Clin Oncol (2015) 3.19
Mammography screening of women in their 40s: impact of changes in screening guidelines. Cancer (2008) 1.54
Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics (2009) 1.48
Outcomes of Active Surveillance for Ductal Carcinoma in Situ: A Computational Risk Analysis. J Natl Cancer Inst (2015) 1.42
Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr (2007) 1.39
Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc Natl Acad Sci U S A (2011) 1.33
Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. J Natl Cancer Inst (2014) 1.27
Development of a clinical decision model for thyroid nodules. BMC Surg (2009) 1.21
Dynamic microsimulation models for health outcomes: a review. Med Decis Making (2010) 1.18
Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev (2008) 1.12
Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst (2014) 1.04
From cancer screening to treatment: service delivery and referral in the National Breast and Cervical Cancer Early Detection Program. Cancer (2014) 1.02
Computational modeling and multilevel cancer control interventions. J Natl Cancer Inst Monogr (2012) 1.02
Contribution of H. pylori and smoking trends to US incidence of intestinal-type noncardia gastric adenocarcinoma: a microsimulation model. PLoS Med (2013) 0.92
Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies. Ann Intern Med (2016) 0.92
Modeling the impact of population screening on breast cancer mortality in the United States. Breast (2011) 0.87
Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004. Cancer (2009) 0.87
Breast cancer screening: controversy of impact. Breast (2013) 0.86
A population-based study of ethnicity and breast cancer stage at diagnosis in Ontario. Curr Oncol (2015) 0.86
Bayesian approaches for comparative effectiveness research. Clin Trials (2011) 0.85
Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer. J Clin Oncol (2009) 0.84
To screen or not to screen for breast cancer? How do modelling studies answer the question? Curr Oncol (2015) 0.83
The screening mammography paradox: better when found, perhaps better not to find. Br J Cancer (2008) 0.83
Modeling and calibration for exposure to time-varying, modifiable risk factors: the example of smoking behavior in India. Med Decis Making (2014) 0.81
Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients. J Natl Cancer Inst (2014) 0.77
Comparative benefit from small tumour size and adjuvant chemotherapy: clues for explaining breast cancer mortality decline. BMC Cancer (2014) 0.75
The Future of Breast Cancer Diagnostics. Breast Care (Basel) (2008) 0.75
Profile of V. Craig Jordan. Proc Natl Acad Sci U S A (2011) 0.75
Geographic variation in the intended choice of adjuvant treatments for women diagnosed with screen-detected breast cancer in Queensland. BMC Public Health (2015) 0.75
Social network effects of nonlifesaving early-stage breast cancer detection on mammography rates. Am J Public Health (2014) 0.75
Competing risks analysis in mortality estimation for breast cancer patients from independent risk groups. Health Care Manag Sci (2013) 0.75
Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet (2009) 7.62
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med (2006) 5.70
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol (2013) 4.72
Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med (2009) 4.60
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol (2009) 4.05
Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst (2005) 4.01
Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol (2002) 3.99
Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst (2007) 3.93
Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA (2006) 3.41
A road map for efficient and reliable human genome epidemiology. Nat Genet (2006) 3.21
siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res (2005) 3.21
Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst (2008) 3.17
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood (2006) 3.13
An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection. J Infect Dis (2012) 3.11
Detection of bladder cancer using a point-of-care proteomic assay. JAMA (2005) 2.88
Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery. J Clin Oncol (2012) 2.85
The flowering time regulator CONSTANS is recruited to the FLOWERING LOCUS T promoter via a unique cis-element. New Phytol (2010) 2.63
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol (2012) 2.53
Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin (2010) 2.45
Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol (2003) 2.41
Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol (2008) 2.40
A multi-institutional analysis of the socioeconomic determinants of breast reconstruction: a study of the National Comprehensive Cancer Network. Ann Surg (2006) 2.29
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica (2008) 2.26
P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol (2007) 2.21
Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol (2005) 2.17
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol (2010) 2.13
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A (2007) 2.11
Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomarkers Prev (2006) 2.04
DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst (2002) 2.04
Chronic kidney disease and cognitive function in older adults: findings from the chronic renal insufficiency cohort cognitive study. J Am Geriatr Soc (2010) 2.03
'Chemobrain' in breast carcinoma?: a prologue. Cancer (2004) 1.98
Genome-wide association study of glioma and meta-analysis. Hum Genet (2012) 1.96
Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol (2004) 1.91
Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer (2008) 1.88
Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum Mol Genet (2011) 1.83
The basic helix-loop-helix transcription factor PIF5 acts on ethylene biosynthesis and phytochrome signaling by distinct mechanisms. Plant Cell (2007) 1.73
Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int (2006) 1.70
Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res (2007) 1.68
Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol (2012) 1.65
A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial. Biometrics (2005) 1.64
Imaging of breast cancer diagnosed and treated with chemotherapy during pregnancy. Radiology (2006) 1.62
The emergence of networks in human genome epidemiology: challenges and opportunities. Epidemiology (2007) 1.61
Survival in cancer patients undergoing in-hospital cardiopulmonary resuscitation: a meta-analysis. Resuscitation (2006) 1.59
Statistical methods for analyzing right-censored length-biased data under cox model. Biometrics (2009) 1.58
Folate pathway polymorphisms predict deficits in attention and processing speed after childhood leukemia therapy. Pediatr Blood Cancer (2011) 1.55
Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res (2005) 1.49
Monitoring late-onset toxicities in phase I trials using predicted risks. Biostatistics (2007) 1.48
Defining the optimal parameters for hairpin-based knockdown constructs. RNA (2007) 1.48
Robot assisted extended pelvic lymphadenectomy at radical cystectomy: lymph node yield compared with second look open dissection. J Urol (2010) 1.48
Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer (2006) 1.47
Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res (2014) 1.46
Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer (2010) 1.46
Functional organization of a neural network for aversive olfactory learning in Caenorhabditis elegans. Neuron (2010) 1.43
Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol (2012) 1.42
Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. Biostatistics (2010) 1.42
Development of new cancers in patients with DCIS: the M.D. Anderson experience. Ann Surg Oncol (2007) 1.42
Increased apoptosis in metastatic human colonic adenocarcinomas. Cancer Biol Ther (2002) 1.42
GLIOGENE an International Consortium to Understand Familial Glioma. Cancer Epidemiol Biomarkers Prev (2007) 1.42
Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. J Clin Oncol (2010) 1.40
Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer (2005) 1.40
Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol (2004) 1.39
The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther (2011) 1.36
The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol (2005) 1.35
Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Cancer (2003) 1.35
A renal mass in the setting of a nonrenal malignancy: When is a renal tumor biopsy appropriate? Cancer (2004) 1.35
Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol (2006) 1.35
A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation. Proc Natl Acad Sci U S A (2008) 1.33
Functional profiling reveals that only a small number of phytochrome-regulated early-response genes in Arabidopsis are necessary for optimal deetiolation. Plant Cell (2006) 1.31
Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res (2008) 1.30
Development of a tightly regulated U6 promoter for shRNA expression. FEBS Lett (2004) 1.30
High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays. BMC Med Genomics (2009) 1.29
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res (2013) 1.29
Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol (2004) 1.28
Institutional variation in the surgical treatment of breast cancer: a study of the NCCN. Ann Surg (2011) 1.28
Glutathione S-transferase polymorphisms and survival in primary malignant glioma. Clin Cancer Res (2004) 1.27
Transcriptomic and genomic evolution under constant cold in Antarctic notothenioid fish. Proc Natl Acad Sci U S A (2008) 1.26
Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol (2008) 1.26
Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res (2006) 1.24
Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol (2007) 1.23
The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism. J Clin Endocrinol Metab (2012) 1.23
p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One (2012) 1.22
Marginal analysis of correlated failure time data with informative cluster sizes. Biometrics (2007) 1.22
Clinical investigation: regional nodal failure patterns in breast cancer patients treated with mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.22
Pheochromocytoma/Paraganglioma: Review of perioperative management of blood pressure and update on genetic mutations associated with pheochromocytoma. J Clin Hypertens (Greenwich) (2013) 1.19
Women age < or = 35 years with primary breast carcinoma: disease features at presentation. Cancer (2005) 1.19
Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clin Cancer Res (2008) 1.18
PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival. Blood (2003) 1.17
A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk. Acta Oncol (2010) 1.17
Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol (2002) 1.16
Genetic advances in glioma: susceptibility genes and networks. Curr Opin Genet Dev (2010) 1.14
Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. J Urol (2006) 1.14
Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial. J Clin Oncol (2004) 1.13
Improvement of xylose fermentation in respiratory-deficient xylose-fermenting Saccharomyces cerevisiae. Metab Eng (2011) 1.12
Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev (2008) 1.12
A Ser49Cys variant in the ataxia telangiectasia, mutated, gene that is more common in patients with breast carcinoma compared with population controls. Cancer (2004) 1.11
Mammography capacity impact on screening rates and breast cancer stage at diagnosis. Am J Prev Med (2009) 1.11
Phytochrome phosphorylation modulates light signaling by influencing the protein-protein interaction. Plant Cell (2004) 1.11